Zhuhai Sailong Pharmaceutical Co Ltd (002898) - Total Liabilities
Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) has total liabilities worth CN¥477.34 Million CNY (≈ $69.85 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002898 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Zhuhai Sailong Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhuhai Sailong Pharmaceutical Co Ltd assets under control.
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhuhai Sailong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hemostemix Inc
V:HEM
|
Canada | CA$4.80 Million |
|
Finsbury Growth & Income Trust
LSE:FGT
|
UK | GBX34.10 Million |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
USA | $201.59 Million |
|
Culpeo Minerals Ltd
AU:CPO
|
Australia | AU$133.18K |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Viking Mines Ltd
AU:VKA
|
Australia | AU$370.98K |
|
Af Legal Group Ltd
AU:AFL
|
Australia | AU$18.06 Million |
|
Langgeng Makmur Industri Tbk
JK:LMPI
|
Indonesia | Rp596.83 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Zhuhai Sailong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002898 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhuhai Sailong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total liabilities of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥447.95 Million ≈ $65.55 Million |
+44.99% |
| 2024-12-31 | CN¥308.95 Million ≈ $45.21 Million |
+11.15% |
| 2023-12-31 | CN¥277.96 Million ≈ $40.67 Million |
-13.58% |
| 2022-12-31 | CN¥321.64 Million ≈ $47.07 Million |
+0.79% |
| 2021-12-31 | CN¥319.12 Million ≈ $46.70 Million |
+40.61% |
| 2020-12-31 | CN¥226.96 Million ≈ $33.21 Million |
+28.26% |
| 2019-12-31 | CN¥176.95 Million ≈ $25.89 Million |
+91.71% |
| 2018-12-31 | CN¥92.30 Million ≈ $13.51 Million |
-4.35% |
| 2017-12-31 | CN¥96.50 Million ≈ $14.12 Million |
+88.43% |
| 2016-12-31 | CN¥51.21 Million ≈ $7.49 Million |
-0.63% |
| 2015-12-31 | CN¥51.53 Million ≈ $7.54 Million |
+5.32% |
| 2014-12-31 | CN¥48.93 Million ≈ $7.16 Million |
-34.27% |
| 2013-12-31 | CN¥74.44 Million ≈ $10.89 Million |
-- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more